SELLAS's 2025 Financial Update Omits Critical REGAL Milestone, Highlighting Persistent Timeline Risk

What happened

SELLAS Life Sciences reported its full-year 2025 financial results on March 19, 2026, in a corporate update that reiterated continued advancement of the pivotal Phase 3 REGAL trial for galinpepimut-S in AML. However, the announcement notably did not confirm that the 80th overall survival event has been reached, which is the mechanical trigger for the final analysis as per prior disclosures. According to the DeepValue report, the trial remained at 72 events as of December 26, 2025, and the company had committed to announcing the 80th event immediately upon occurrence. The update also lacked evidence of the SLS009 frontline study initiation, which management had previously guided to begin enrolling by Q1 2026, failing to provide operational proof for this secondary asset. Financially, while the full results may detail ongoing cash burn and dilution, the absence of these key milestones leaves the investment thesis in a precarious holding pattern.

Implication

The omission of the 80th REGAL event announcement delays the binary catalyst, increasing the likelihood of timeline drift and potential dilution from future financings to extend the runway. Without confirmation of SLS009 trial initiation, the secondary asset fails to provide narrative support, leaving the stock overly dependent on a single, uncertain outcome. Persistent reliance on equity-linked instruments, evidenced by rising share counts, continues to erode per-share value, even if clinical progress eventually occurs. Market sentiment, already framed around short-term catalysts, may sour if these milestones are not met by mid-2026, leading to compressed valuation premiums and heightened volatility. Therefore, investors must closely monitor for the 80th event PR and SLS009 execution proof, as their absence would signal a deterioration in the base case scenario and warrant exit.

Thesis delta

The core thesis remains unchanged, as the update provides no substantive progress to alter the critical path dependent on the 80th REGAL event and SLS009 trial start. However, the passage of time without milestone achievement subtly shifts probabilities toward the bear scenario, where delays increase dilution risk and erode per-share upside. Investors should reassess if these catalysts are not delivered by the 2026 mid-year checkpoints outlined in the DeepValue report.